![Xolair® (Omalizumab) - UnitedHealthcareOnline.com](http://s1.studyres.com/store/data/001788632_1-fb6d80d88ce106c3257b43ca638881ba-300x300.png)
Xolair® (Omalizumab) - UnitedHealthcareOnline.com
... months, forced expiratory volume in 1 s (FEV1) improved by 4.9% (p=0.023), and inhaled corticosteroid dose decreased by 30% (p<0.001). Six patients stopped omalizumab for related significant adverse events. Omalizumab improved asthma control in children with severe allergic asthma and was generally ...
... months, forced expiratory volume in 1 s (FEV1) improved by 4.9% (p=0.023), and inhaled corticosteroid dose decreased by 30% (p<0.001). Six patients stopped omalizumab for related significant adverse events. Omalizumab improved asthma control in children with severe allergic asthma and was generally ...
Collagen Cross-linking with Riboflavin in a Hypotonic Solution with
... Studies were carried out in rabbits to determine the effect of cross-linking on the corneal endothelium 5. Thirty four eyes were treated with various endothelial doses of UVA ranging from 0.16 – 0.9 J/cm2 (0.09 – 0.5 mW/cm2, 370nm). In rabbit corneas of thickness less than 400µ, the endothelial UVA ...
... Studies were carried out in rabbits to determine the effect of cross-linking on the corneal endothelium 5. Thirty four eyes were treated with various endothelial doses of UVA ranging from 0.16 – 0.9 J/cm2 (0.09 – 0.5 mW/cm2, 370nm). In rabbit corneas of thickness less than 400µ, the endothelial UVA ...
Reyataz label - HIV Drug Resistance Database
... some patients. Use with caution in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. (5.2, 6.4, 7.3, 12.2, 17.3) ...
... some patients. Use with caution in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. (5.2, 6.4, 7.3, 12.2, 17.3) ...
PREZISTA® - Janssen
... Product Information. Hepatic impairment Darunavir is primarily metabolised and eliminated by the liver. In a multiple dose study with PREZISTA co-administered with ritonavir (600/100 mg) twice daily, it was demonstrated that the steady-state pharmacokinetic parameters of darunavir in patients with m ...
... Product Information. Hepatic impairment Darunavir is primarily metabolised and eliminated by the liver. In a multiple dose study with PREZISTA co-administered with ritonavir (600/100 mg) twice daily, it was demonstrated that the steady-state pharmacokinetic parameters of darunavir in patients with m ...
(tazarotene) Gel,...TAZORAC
... envelope formation in cultured human keratinocytes. The clinical significance of these findings is unknown. Pharmacokinetics: Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Little parent compound could be detected in the plasm ...
... envelope formation in cultured human keratinocytes. The clinical significance of these findings is unknown. Pharmacokinetics: Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Little parent compound could be detected in the plasm ...
Octreotide Acetate Injection in a prefilled syringe
... INDICATIONS AND USAGE: Acromegaly: Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate a ...
... INDICATIONS AND USAGE: Acromegaly: Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate a ...
Product Information: Lisdexamfetamine dimesilate
... Australia Pty Limited PM-2012-01494-3-1 Date of Finalisation 23 October 2013. This Product Information was approved at the time this AusPAR was published. Product Information ...
... Australia Pty Limited PM-2012-01494-3-1 Date of Finalisation 23 October 2013. This Product Information was approved at the time this AusPAR was published. Product Information ...
PPIs May Reduce Effectiveness Of Clopidogrel (PLAVIX®)
... Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008;51:256-60. Pezella E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibito ...
... Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008;51:256-60. Pezella E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibito ...
Lay summary Page 2 Scientific discussion
... bioequivalence/bioavailability for such preparations where it is considered that the excipients will not interfere with bioavailability of the drug. In this instance there are no concerns as the same excipients are used in this formulation compared to that of the innovator. ...
... bioequivalence/bioavailability for such preparations where it is considered that the excipients will not interfere with bioavailability of the drug. In this instance there are no concerns as the same excipients are used in this formulation compared to that of the innovator. ...
American Society of Clinical Oncology Guideline for Antiemetics in
... This section is followed by a 2006 literature update section. Whenever possible, the Update Committee preserved the organizing framework of the 1999 guideline document. Recommendations and supporting evidence for major new topics, such as aprepitant and palonosetron, have been distributed in the app ...
... This section is followed by a 2006 literature update section. Whenever possible, the Update Committee preserved the organizing framework of the 1999 guideline document. Recommendations and supporting evidence for major new topics, such as aprepitant and palonosetron, have been distributed in the app ...
Systemic effects of salbutamol and salmeterol in patients
... available for twice daily administration. Clinical trials suggest that patients with asthma are better controlled by a twice daily dose of 50,g salmeterol than by four times daily administration of 200 gg and 400 jg salbutamol.1-3 The extent to which this beneficial effect of salmeterol is the resul ...
... available for twice daily administration. Clinical trials suggest that patients with asthma are better controlled by a twice daily dose of 50,g salmeterol than by four times daily administration of 200 gg and 400 jg salbutamol.1-3 The extent to which this beneficial effect of salmeterol is the resul ...
Depakene/Depakote/ Depakote
... Depakene (valproic acid) and Depakote (divalproex sodium) are better known as anticonvulsants—medications for treating epilepsy. This may present some confusion for patients, as well as their families, when they are prescribed an anticonvulsant without a history of seizures. In the past decade, anti ...
... Depakene (valproic acid) and Depakote (divalproex sodium) are better known as anticonvulsants—medications for treating epilepsy. This may present some confusion for patients, as well as their families, when they are prescribed an anticonvulsant without a history of seizures. In the past decade, anti ...
QA248_4Pyridostigmine_neostigmine_FINAL
... neostigmine can be administered both orally and parenterally.(2-4) For the parenteral route, neostigmine is licensed for the treatment of myasthenia gravis when given subcutaneous (SC) or intramuscular (IM); the intravenous (IV) route is licensed for reversal of non-depolarising neuromuscular blocka ...
... neostigmine can be administered both orally and parenterally.(2-4) For the parenteral route, neostigmine is licensed for the treatment of myasthenia gravis when given subcutaneous (SC) or intramuscular (IM); the intravenous (IV) route is licensed for reversal of non-depolarising neuromuscular blocka ...
- Boehringer Ingelheim (Canada)
... Hypoxic States: Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on JENTA ...
... Hypoxic States: Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on JENTA ...
ENDOGENOUS ENDOPHTHALMITIS
... more recently. Subconjunctival and topical antibiotics are also employed as well as intravitreal and oral steroids. The role of systemic antibiotic analyzed by the endophthalmitis vitrectomy study group (EVS) is not applicable for the endogenous forms. -Fungal: intravitreal and intravenous amphoteri ...
... more recently. Subconjunctival and topical antibiotics are also employed as well as intravitreal and oral steroids. The role of systemic antibiotic analyzed by the endophthalmitis vitrectomy study group (EVS) is not applicable for the endogenous forms. -Fungal: intravitreal and intravenous amphoteri ...
1 6111 METRONIDAZOLE VAGINAL GEL, 0.75%
... of patients with Crohn’s disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in a second study, no increase in chromosome aberrations was reported in patients with Crohn’s disease who were treated with metronidazole for 8 months. Fertility studies have been ...
... of patients with Crohn’s disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in a second study, no increase in chromosome aberrations was reported in patients with Crohn’s disease who were treated with metronidazole for 8 months. Fertility studies have been ...
Pharmacology GI – Cards
... Mech.: Binds to PBPs, blocks activity of transpeptidases in terminal stages of cell wall formation. Bactericidal. Absorption: Acid stable. Good oral (better than ampicillin). Distrib.: Widely distributed, little CSF unless meninges inflamed. Metab.: Excretion, t_: Rapidly elim. by kidneys (probeneci ...
... Mech.: Binds to PBPs, blocks activity of transpeptidases in terminal stages of cell wall formation. Bactericidal. Absorption: Acid stable. Good oral (better than ampicillin). Distrib.: Widely distributed, little CSF unless meninges inflamed. Metab.: Excretion, t_: Rapidly elim. by kidneys (probeneci ...
Serevent - GlaxoSmithKline
... changes (e.g. hyperglycemia, hypokalemia). There have been very rare reports of increases in blood glucose levels (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions) and this should be considered when prescribing to patients with a history of diabetes mellitus. Doses of the related beta2-adr ...
... changes (e.g. hyperglycemia, hypokalemia). There have been very rare reports of increases in blood glucose levels (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions) and this should be considered when prescribing to patients with a history of diabetes mellitus. Doses of the related beta2-adr ...
AusPAR: Doxycycline monohydrate
... Doxycycline immediate release products are currently used ‘off-label’ for the treatment of rosacea. Typical recommended doses are 50 – 100 mg per day.1,2 The mechanism of action of doxycycline in rosacea is thought to be unrelated to its antimicrobial effect. The sponsor’s formulation development wa ...
... Doxycycline immediate release products are currently used ‘off-label’ for the treatment of rosacea. Typical recommended doses are 50 – 100 mg per day.1,2 The mechanism of action of doxycycline in rosacea is thought to be unrelated to its antimicrobial effect. The sponsor’s formulation development wa ...
diltiazem hydrochloride injection
... significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to ...
... significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to ...
PRODUCT MONOGRAPH PrCELEBREX ® (celecoxib) Capsules
... aplastic anemia and agranulocytosis) associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) are rare, but could occur with severe consequences. Anemia is sometimes seen in patients receiving NSAIDs, including CELEBREX. This may be due to fluid retention, GI blood loss, or an incomp ...
... aplastic anemia and agranulocytosis) associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) are rare, but could occur with severe consequences. Anemia is sometimes seen in patients receiving NSAIDs, including CELEBREX. This may be due to fluid retention, GI blood loss, or an incomp ...
alertec - Shire Canada
... (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide post-marketing experience. The reporting rate of TEN and SJS associated with modafinil use, which is generally accepted to be an underestimate due to under-reporting, exceeds t ...
... (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide post-marketing experience. The reporting rate of TEN and SJS associated with modafinil use, which is generally accepted to be an underestimate due to under-reporting, exceeds t ...
Public Assessment Report Scientific discussion Tracydal 20 mg, film
... the Netherlands has granted a marketing authorisation for Tracydal 20 mg film-coated tablets from Daleco Pharma b.v. Following extensive deliberation of the benefit-risk balance the Board concluded that additional risk minimisation measures are required to warrant safe use of this medicine. Educatio ...
... the Netherlands has granted a marketing authorisation for Tracydal 20 mg film-coated tablets from Daleco Pharma b.v. Following extensive deliberation of the benefit-risk balance the Board concluded that additional risk minimisation measures are required to warrant safe use of this medicine. Educatio ...
Modafinil Bluefish Tablet ENG SmPC
... Steroidal contraceptives: The effectiveness of steroidal contraceptives may be impaired due to induction of CYP3A4/5 by modafinil. Alternative or concomitant methods of contraception are recommended for patients treated with modafinil. Adequate contraception will require continuation of these method ...
... Steroidal contraceptives: The effectiveness of steroidal contraceptives may be impaired due to induction of CYP3A4/5 by modafinil. Alternative or concomitant methods of contraception are recommended for patients treated with modafinil. Adequate contraception will require continuation of these method ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... associated with 30% of all maternal deaths and as much as 22% of all perinatal deaths. 3 It has been estimated by WHO (World Health Organization) that worldwide approximately 50,000 women will die each year from hypertensive disorders of pregnancy.4 Severe PIH requires prompt treatment because of ri ...
... associated with 30% of all maternal deaths and as much as 22% of all perinatal deaths. 3 It has been estimated by WHO (World Health Organization) that worldwide approximately 50,000 women will die each year from hypertensive disorders of pregnancy.4 Severe PIH requires prompt treatment because of ri ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.